343 related articles for article (PubMed ID: 22566591)
1. European Organization for the Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) host factors and invasive fungal infections in patients with haematological malignancies.
Hoenigl M; Strenger V; Buzina W; Valentin T; Koidl C; Wölfler A; Seeber K; Valentin A; Strohmeier AT; Zollner-Schwetz I; Raggam RB; Urban C; Lass-Flörl C; Linkesch W; Krause R
J Antimicrob Chemother; 2012 Aug; 67(8):2029-33. PubMed ID: 22566591
[TBL] [Abstract][Full Text] [Related]
2. Epidemiology of invasive fungal infections and rationale for antifungal therapy in patients with haematological malignancies.
Hoenigl M; Zollner-Schwetz I; Sill H; Linkesch W; Lass-Flörl C; Schnedl WJ; Krause R
Mycoses; 2011 Sep; 54(5):454-9. PubMed ID: 20406398
[TBL] [Abstract][Full Text] [Related]
3. Indications and outcomes of antifungal therapy in French patients with haematological conditions or recipients of haematopoietic stem cell transplantation.
Herbrecht R; Caillot D; Cordonnier C; Auvrignon A; Thiébaut A; Brethon B; Michallet M; Mahlaoui N; Bertrand Y; Preziosi P; Ruiz F; Gorin NC; Gangneux JP
J Antimicrob Chemother; 2012 Nov; 67(11):2731-8. PubMed ID: 22850692
[TBL] [Abstract][Full Text] [Related]
4. Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC/MSG 2008 definitions of invasive mould disease.
Cornely OA; Maertens J; Bresnik M; Ebrahimi R; Dellow E; Herbrecht R; Donnelly JP
Mycoses; 2011 Sep; 54(5):e449-55. PubMed ID: 21039936
[TBL] [Abstract][Full Text] [Related]
5. Hema e-Chart registry of invasive fungal infections in haematological patients: improved outcome in recent years in mould infections.
Nosari AM; Caira M; Pioltelli ML; Fanci R; Bonini A; Cattaneo C; Castagnola C; Capalbo SF; De Fabritiis P; Mettivier V; Morselli M; Pastore D; Aversa F; Rossi G; Pagano L;
Clin Microbiol Infect; 2013 Aug; 19(8):757-62. PubMed ID: 23279327
[TBL] [Abstract][Full Text] [Related]
6. Clinical experience with posaconazole prophylaxis--a retrospective analysis in a haematological unit.
Hahn J; Stifel F; Reichle A; Holler E; Andreesen R
Mycoses; 2011 Jan; 54 Suppl 1():12-6. PubMed ID: 21126267
[TBL] [Abstract][Full Text] [Related]
7. Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998-2009.
Campo M; Lewis RE; Kontoyiannis DP
J Infect; 2010 May; 60(5):331-7. PubMed ID: 20138081
[TBL] [Abstract][Full Text] [Related]
8. Posaconazole prophylaxis--impact on incidence of invasive fungal disease and antifungal treatment in haematological patients.
Peterson L; Ostermann J; Rieger H; Ostermann H; Rieger CT
Mycoses; 2013 Nov; 56(6):651-8. PubMed ID: 23710592
[TBL] [Abstract][Full Text] [Related]
9. Treatment of invasive fungal infections in high risk hematological patients. The outcome with liposomal amphotericin B is not negatively affected by prior administration of mold-active azoles.
De la Serna J; Jarque I; López-Jiménez J; Fernández-Navarro JM; Gómez V; Jurado M; Pascual A; Serrano J; Romero M; Vallejo C
Rev Esp Quimioter; 2013 Mar; 26(1):64-9. PubMed ID: 23546466
[TBL] [Abstract][Full Text] [Related]
10. Risk of reactivation of a recent invasive fungal infection in patients with hematological malignancies undergoing further intensive chemo-radiotherapy. A single-center experience and review of the literature.
Martino R; Lopez R; Sureda A; Brunet S; Domingo-Albós A
Haematologica; 1997; 82(3):297-304. PubMed ID: 9234575
[TBL] [Abstract][Full Text] [Related]
11. Therapy with antifungals decreases the diagnostic performance of PCR for diagnosing invasive aspergillosis in bronchoalveolar lavage samples of patients with haematological malignancies.
Reinwald M; Hummel M; Kovalevskaya E; Spiess B; Heinz WJ; Vehreschild JJ; Schultheis B; Krause SW; Claus B; Suedhoff T; Schwerdtfeger R; Reuter S; Kiehl MG; Hofmann WK; Buchheidt D
J Antimicrob Chemother; 2012 Sep; 67(9):2260-7. PubMed ID: 22740590
[TBL] [Abstract][Full Text] [Related]
12. Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies.
Maertens J
Eur J Haematol; 2007 Apr; 78(4):275-82. PubMed ID: 17241370
[TBL] [Abstract][Full Text] [Related]
13. Empiric vs. preemptive antifungal treatment: an appraisal of treatment strategies in haematological patients.
Rieger CT; Ostermann H
Mycoses; 2008; 51 Suppl 1():31-4. PubMed ID: 18471159
[TBL] [Abstract][Full Text] [Related]
14. Invasive fungal infections: epidemiology and analysis of antifungal prescriptions in onco-haematology.
des Champs-Bro B; Leroy-Cotteau A; Mazingue F; Pasquier F; François N; Corm S; Lemaitre L; Poulain D; Yakoub-Agha I; Alfandari S; Sendid B
J Clin Pharm Ther; 2011 Apr; 36(2):152-60. PubMed ID: 21366643
[TBL] [Abstract][Full Text] [Related]
15. Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions.
Safdar A; Rodriguez GH; Lichtiger B; Dickey BF; Kontoyiannis DP; Freireich EJ; Shpall EJ; Raad II; Kantarjian HM; Champlin RE
Cancer; 2006 Jun; 106(12):2664-71. PubMed ID: 16691620
[TBL] [Abstract][Full Text] [Related]
16. New category of probable invasive pulmonary aspergillosis in haematological patients.
Girmenia C; Guerrisi P; Frustaci AM; Fama A; Finolezzi E; Perrone S; Gentile G; Collerone F; Brocchieri S; Guerrisi V
Clin Microbiol Infect; 2012 Oct; 18(10):990-6. PubMed ID: 21999366
[TBL] [Abstract][Full Text] [Related]
17. The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole.
Barreto JN; Beach CL; Wolf RC; Merten JA; Tosh PK; Wilson JW; Hogan WJ; Litzow MR
Am J Hematol; 2013 Apr; 88(4):283-8. PubMed ID: 23460251
[TBL] [Abstract][Full Text] [Related]
18. Delayed ABLC prophylaxis after allogeneic stem-cell transplantation.
Jansen J; Akard LP; Wack MF; Thompson JM; Dugan MJ; Leslie JK; Mattison R
Mycoses; 2006 Sep; 49(5):397-404. PubMed ID: 16922792
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies.
Kurosawa M; Yonezumi M; Hashino S; Tanaka J; Nishio M; Kaneda M; Ota S; Koda K; Suzuki N; Yoshida M; Hirayama Y; Takimoto R; Torimoto Y; Mori A; Takahashi T; Iizuka S; Ishida T; Kobayashi R; Oda T; Sakai H; Yamamoto S; Takahashi F; Fukuhara T
Int J Hematol; 2012 Dec; 96(6):748-57. PubMed ID: 23111539
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for breakthrough invasive fungal infection during secondary prophylaxis.
Cornely OA; Böhme A; Reichert D; Reuter S; Maschmeyer G; Maertens J; Buchheidt D; Paluszewska M; Arenz D; Bethe U; Effelsberg J; Lövenich H; Sieniawski M; Haas A; Einsele H; Eimermacher H; Martino R; Silling G; Hahn M; Wacker S; Ullmann AJ; Karthaus M;
J Antimicrob Chemother; 2008 Apr; 61(4):939-46. PubMed ID: 18272515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
